Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Ultragenyx Pharmaceutical Inc. < Previous 1 2 Next > Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) December 21, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH) December 18, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx to Participate at Investor Conferences in November November 20, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) November 17, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx to Participate in the Jefferies London Healthcare Conference November 07, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update November 02, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx to Host Conference Call for Third Quarter 2023 Financial Results and Corporate Update October 26, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares October 23, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) October 20, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants October 18, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Announces Proposed Public Offering of Common Stock October 17, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (OI), Angelman Syndrome (AS) and Wilson Disease October 16, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) October 12, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI) October 09, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers MREO RARE Ultragenyx to Present Pipeline Update at Analyst Day on Monday, October 16, 2023 October 05, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) September 20, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx to Participate at Investor Conferences in September August 31, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) August 18, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update August 03, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease July 31, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx to Host Conference Call for Second Quarter 2023 Financial Results and Corporate Update July 27, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) July 18, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy July 12, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) July 06, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers MREO RARE Ultragenyx Opens New Gene Therapy Manufacturing Facility in Bedford, Continuing its Expansion in Massachusetts June 21, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) June 20, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference June 07, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI) June 05, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy Summit May 19, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) May 18, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.